Bioceltix S.A. (XI3.F)

14.04 -0.12 (-0.85%) As of 03:29PM CEST. Market open.

Bioceltix S.A.

Building III
Bierutowska 57-59 Street
Wroclaw 51-317
Poland
48 71 880 8771
https://bioceltix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 28

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Lukasz Bzdzion	President of the Management Board	367.52k	N/A	N/A
Mr. Pawel Wielgus	Member of the Management Board	359.13k	N/A	N/A
Andrij Wlach	Chief Financial Officer	N/A	N/A	N/A
Mr. Grzegorz Ostropolski	Chief Operating Officer	N/A	N/A	N/A
Dr. Jakub Grzesiak Ph.D.	Technology Director	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.

Corporate governance

Bioceltix S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.